

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings and versions of claims in this application.

**Listing of Claims:**

1. (Currently Amended) A method of ~~treating a T-cell mediated inflammation disorder in~~ for up regulating runt-related transcription factor3 (RUNX3) expression in a subject, which comprises delivering an active agent to immune cells of said subject having low activity or no activity of runt-related transcription 3 factor (RUNX3) gene product, the method comprising delivering an wherein said active agent that induces expression or over-expression of RUNX3 ~~to-in the~~ said immune cells of said subject, thereby inhibiting the proliferation of T-cells in said subject.
2. (Currently Amended) The method of claim 1, wherein ~~the~~ said immune cells are selected from the group consisting of thymocytes and dendritic cells (DC).
3. (Currently Amended) The method of claim 2, wherein ~~the~~ said immune cells of ~~the subject~~ are dendritic cells.
4. (Currently Amended) The method of claim 3, wherein ~~the~~ said active agent reduces the proportion of mature dendritic cells versus immature dendritic cells in said subject.
5. (Currently Amended) The method of claim 4, wherein ~~the~~ said reduction in the proportion of mature dendritic cells versus immature dendritic cells is determined by a reduction in the proportion of dendritic cells expressing CD80, CD86, MHC class II and OX40L.

6. (Currently Amended) The method of claim 1, wherein ~~the~~ said active agent ~~comprises is selected from the group consisting of~~ a polynucleotide encoding RUNX3 ~~or and~~ a polynucleotide encoding a RUNX3 promoter activator.

7. (Currently Amended) The method of claim 6, wherein ~~the~~ said polynucleotides further comprises a viral-based vector.

8. (Currently Amended) The method of claim 1, wherein ~~the~~ said delivery step is performed *ex vivo*.

9. (Currently Amended) The method of claim 1, wherein said immune cells are from a subject with a the T-cell mediated inflammation disorder that is selected from the group consisting of asthma, allergic asthma, Crohn's disease, and ulcerative colitis.

10-12. (Canceled)

13. (Currently Amended) A method ~~of attenuating dendritic cell maturation for reducing the proportion of mature dendritic cells versus immature dendritic cells~~ in a subject, comprising:

delivering an active agent to immune cells of said subject having low activity or no activity of runt-related transcription 3 factor (RUNX3) gene product, ~~the method comprising delivering an wherein said~~ active agent that induces expression or over-expression of RUNX3 ~~to in the said immune dendritic cells of said subject, thereby attenuating dendritic cell maturation reducing the proportion of mature dendritic cells versus immature dendritic cells~~ in said subject.

14-48. (Canceled)

49. (New) The method of claim 13, wherein said immune cells are selected from the group consisting of thymocytes and dendritic cells (DC).

50. (New) The method of claim 13, wherein said active agent is selected from the group consisting of a polynucleotide encoding RUNX3 and a polynucleotide encoding a RUNX3 promoter activator.

51. (New) The method of claim 50, wherein said polynucleotides further comprise a viral-based vector.